Arvinas Strategy and Business Model

Executive Overview

Arvinas is a New Haven, Connecticut-based clinical-stage biotechnology company focused on targeted protein degradation, a drug-discovery approach designed to remove disease-causing proteins rather than merely inhibit them. Founded in 2013 around research associated with Yale scientist Craig Crews, Arvinas is one of the companies most closely associated with translating the PROteolysis TArgeting Chimera (PROTAC) concept into a drug-development platform. Its strategy is centered on building differentiated oral medicines, primarily in oncology, that may work where conventional inhibitors or endocrine therapies are less effective. The company’s lead asset is vepdegestrant, an estrogen receptor degrader being advanced with Pfizer for estrogen receptor-positive/human epidermal growth factor receptor 2-negative breast cancer, alongside wholly owned programs such as ARV-766 in prostate cancer and earlier pipeline candidates intended to show the platform can address additional targets. Arvinas operates mainly from the United States, but its clinical-development and partnering footprint is global through multi-country trials and large pharmaceutical collaborators. In FY2024, Arvinas reported revenue of #N/A, generated primarily from collaboration agreements rather than product sales.

Arvinas at a Glance

Logo
Common name	Arvinas
Full legal name	Arvinas, Inc.
Headquarters	New Haven, Connecticut, United States
Ownership	Public company
Ticker	ARVN
Exchange	NASDAQ
Market Cap	$525.20M
Revenue (FY2024)	#N/A
Founding / major historical milestones	Founded in 2013; Nasdaq IPO in 2018; Genentech collaboration announced in 2020; Pfizer collaboration for vepdegestrant announced in 2021; subsequent move into later-stage clinical development in oncology
Industry or industries	Clinical-stage biotechnology; oncology drug discovery and development; targeted protein degradation
Key products or services	Clinical-stage oral protein degraders, including vepdegestrant and ARV-766; discovery platform and collaboration/licensing arrangements
Geographic footprint	U.S.-based research and corporate operations with global clinical-development and partner reach
Business segments as officially reported	One operating and reportable segment
Company website	https://www.arvinas.com

1. What Is the Strategy of Arvinas?

Arvinas’s public materials consistently frame the company as a targeted protein degradation company trying to convert a scientific platform into a pipeline of differentiated medicines. Using the Playing to Win framework, the strategy is less about broad diversification and more about proving that protein degradation can produce better clinical outcomes in selected diseases, then extending that advantage across additional targets.

1. 1a. What is the winning aspiration of Arvinas?

   Arvinas’s winning aspiration is to become a leading targeted protein degradation company by bringing degraders to patients and establishing the modality as a repeatable drug-discovery engine. In practice, “winning” means more than publishing attractive preclinical science. It means demonstrating that its degraders can succeed in human trials, create meaningful clinical differentiation, and support a durable pipeline and partnership model. Public disclosures have emphasized delivering transformative medicines for patients with serious diseases, particularly cancer. Arvinas has not centered investor messaging on a long-range revenue target; instead, its more concrete public objectives have been clinical and strategic milestones such as advancing vepdegestrant, progressing wholly owned oncology programs, and broadening the reach of the platform.

2. 1b. Where does Arvinas play?

   Arvinas currently plays primarily in oncology, especially tumor settings where degradation may offer advantages over inhibition or conventional endocrine therapy. The clearest focus areas have been estrogen receptor-driven breast cancer and androgen receptor-driven prostate cancer, with additional pipeline work extending into other oncology targets and selected partnered discovery areas. Geographically, Arvinas remains U.S.-centered operationally, but it plays in global drug development through multinational clinical trials and through collaborators with worldwide commercialization capabilities. Economically, the company also plays in biopharma partnering: large pharmaceutical companies are not just development collaborators, but current sources of revenue.

3. 1c. How does Arvinas plan to win?

   Arvinas plans to win by showing that its orally bioavailable degraders can remove disease-driving proteins more completely or more durably than traditional drugs that merely block activity. In breast cancer, the idea is that a degrader of the estrogen receptor may outperform standard endocrine approaches in parts of the treatment pathway, especially where resistance biology matters. In prostate cancer, the same logic applies to the androgen receptor. The company’s competitive formula combines three elements: a modality with differentiated biology, biomarker-informed clinical development, and selective partnering to add scale where Arvinas would otherwise be capital constrained. The Pfizer relationship around vepdegestrant is the clearest example of this model.

4. 1d. What capabilities must Arvinas have in place?

   To execute this strategy, Arvinas needs strong capabilities in chemical biology, medicinal chemistry, structure-based design, translational science, clinical oncology development, biomarker strategy, intellectual property, and alliance management. Targeted protein degradation is not just a target-selection problem; it requires designing bifunctional molecules with the right potency, selectivity, degradation profile, oral drug-like properties, and manufacturability. Arvinas also needs robust clinical-development capabilities to run trials in competitive oncology markets where enrollment, combination strategy, and patient selection are critical. Because the company relies heavily on collaborators and external development vendors, vendor oversight and governance are also important capabilities.

5. 1e. What management systems does Arvinas require?

   Arvinas needs management systems that support portfolio discipline, milestone-based resource allocation, and collaboration governance. As a clinical-stage biotech, it must continuously decide how much capital to commit to late-stage partnered assets, wholly owned programs, and earlier discovery efforts. That requires formal stage-gate portfolio reviews, tight cash-runway monitoring, and clear development decision points. For partnered assets, Arvinas also needs strong joint steering and operating mechanisms so that programs move efficiently despite shared control. Finally, because the company’s value rests heavily on platform know-how and patent position, it needs disciplined intellectual-property management and data-governance processes.

2. What Are the Current Strategic Initiatives of Arvinas?

As reflected in Arvinas’s FY2024 disclosures and subsequent company updates, the company’s current strategic initiatives are concentrated in a relatively small number of high-value execution priorities.

1. Advance vepdegestrant through late-stage breast-cancer development

   This is the company’s most important near-term initiative. Arvinas and Pfizer have been advancing vepdegestrant in estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced or metastatic breast cancer, with registrational ambitions and multiple settings under evaluation. The strategic goal is not just to show activity, but to define where degradation of the estrogen receptor offers clinically meaningful differentiation versus fulvestrant and other emerging oral endocrine therapies.

2. Build a differentiated role for ARV-766 in prostate cancer

   ARV-766 is Arvinas’s most important wholly owned clinical oncology program. The company has been positioning it in metastatic castration-resistant prostate cancer, particularly where resistance to prior androgen-receptor-pathway therapies may create a rationale for degradation. Strategically, ARV-766 matters because it gives Arvinas a chance to retain more downstream economics than it does in a partnered program while also proving the platform beyond breast cancer.

3. Broaden the pipeline beyond hormone-receptor biology

   Arvinas has disclosed additional oncology pipeline work, including earlier programs intended to demonstrate that targeted protein degradation is not limited to estrogen receptor or androgen receptor biology. This matters strategically because a one- or two-asset story is less valuable than a platform story. Expanding into additional targets raises the probability that Arvinas can become a durable pipeline company rather than a single-program biotech.

4. Use partnerships to combine scientific leverage with commercial scale

   Arvinas has used collaborations to extend the reach of its platform and to help fund development. The Pfizer alliance around vepdegestrant is central, and other research collaborations have supported the broader platform. The strategic logic is clear: Arvinas can keep participating in high-value assets while avoiding the cost of building full global infrastructure too early.

5. Prepare for a more commercial operating model without overbuilding too early

   Although Arvinas remained pre-commercial in FY2024, late-stage development creates a need for launch planning, medical-affairs preparation, market-access thinking, and operating-model design. The company must therefore prepare for possible commercialization while staying capital disciplined. That balance is a recurring strategic theme for development-stage biotechs approaching potential launch.

6. Preserve financial flexibility and prioritize the portfolio

   Because Arvinas’s opportunities are larger than its internal resources, portfolio selection is itself a strategic initiative. Management must decide where to invest directly, where to partner, and which programs merit continued spending based on emerging data. In a company at this stage, capital allocation is inseparable from scientific strategy.

3. What Is the Business Model of Arvinas?

Arvinas’s business model is that of a clinical-stage platform biotech. As of FY2024, it did not have approved products generating recurring commercial sales. Instead, the company monetized its science through collaboration revenue while investing heavily to create future product value.

• What customers actually buy: Today, Arvinas’s paying counterparties are primarily pharmaceutical partners that buy access to specific assets, shared development rights, or discovery capabilities. In the future, if products are approved, customers would buy specialty oncology medicines.
• Recurring versus one-time economics: Current revenue is not highly recurring in the way a subscription or services model would be. It is driven by upfront payments, milestone recognition, collaboration reimbursements, and license accounting. Future product revenue, if achieved, would be repeat-prescription driven but still dependent on treatment duration, label scope, and competitive dynamics.
• Revenue model: The current revenue model is collaboration- and milestone-based. Longer term, the model could include U.S. profit share, ex-U.S. royalties, and direct product sales for wholly owned assets, depending on how Arvinas chooses to commercialize them.
• How pricing power works: Pricing power is mostly prospective rather than current. If Arvinas reaches the market, oncology pricing would depend on demonstrated efficacy, safety, convenience, biomarker-defined differentiation, and payer willingness to reimburse relative to existing standards of care and competing endocrine or prostate-cancer therapies.
• Why the business mix matters: A partnered asset such as vepdegestrant can reduce financing risk and add global reach, but it also limits the share of economics that Arvinas keeps. A wholly owned asset such as ARV-766 carries greater upside if successful, but also higher funding needs and execution burden.
• Margin and cash-generation drivers: Traditional gross margin is not yet the main analytic lens because Arvinas has no large product cost-of-goods base. Operating performance is dominated by research and development expense, clinical-trial spend, manufacturing-for-trials expense, and general and administrative build-out. Cash generation today depends mainly on collaboration payments and financing capacity rather than operating profits.

4. What Products and/or Services Does Arvinas Sell?

Arvinas does not yet have approved marketed products. Its most important offerings are clinical-stage drug candidates and the underlying targeted protein degradation platform that supports internal programs and collaborations.

The highest strategic-value program is vepdegestrant because it has the clearest path to a commercially relevant oncology market. ARV-766 is strategically important because it is a test of Arvinas’s ability to build value in a largely self-controlled asset. Earlier programs matter less near term for revenue, but more for proving breadth.

5. What Are the Key Competitors or Peers of Arvinas?

Because Arvinas is still pre-commercial, the most useful comparison set includes both asset-level competitors in breast and prostate cancer and platform peers in targeted protein degradation.

In practical terms, Arvinas must clear two different competitive bars. First, its individual assets must outperform or complement existing therapies and rival pipeline drugs. Second, its platform must continue to look productive enough to justify premium valuation and partnering interest relative to other degradation companies.

6. What Is the Marketing Strategy of Arvinas?

Arvinas’s current marketing strategy is best understood as scientific and stakeholder communication, not mass commercial promotion. Because the company had no approved products in FY2024, brand advertising and trade promotion were not meaningful parts of the model.

• Scientific marketing: Arvinas builds awareness through data presentations, publications, and oncology congress activity. In biotech, this is the main route to building credibility with investigators, key opinion leaders, potential partners, and investors.
• KOL and investigator engagement: For a company developing oncology drugs, relationships with leading breast- and prostate-cancer centers are crucial. Trial-site quality and physician advocacy matter more than broad consumer marketing.
• Partner-enabled commercialization planning: For vepdegestrant, future commercial messaging will likely rely heavily on the scale and oncology infrastructure of Pfizer, especially outside the United States.
• Biomarker education: If Arvinas commercializes drugs in biomarker-defined populations, education around mutation testing and patient identification becomes part of the go-to-market challenge.
• Corporate communications: Investor relations and alliance communications are strategically important because capital access and partner confidence directly affect Arvinas’s operating runway.

So far, marketing appears to be a supporting capability rather than the company’s primary differentiator. The real differentiator is the science; marketing’s role is to translate that science into physician confidence, partner support, and eventual launch readiness.

7. What Are the Key Customer Segments of Arvinas?

Arvinas has two different customer lenses: its current economic customers and its future therapeutic customers.

• Pharmaceutical partners: Today, this is the most important paying customer segment. Collaboration partners such as Pfizer, and research collaborators where applicable, are the main source of recognized revenue.
• Medical oncologists and cancer centers: If approved, Arvinas’s products would initially be specialty medicines prescribed by oncologists, especially those treating breast cancer and prostate cancer in advanced-disease settings.
• Hospitals, oncology clinics, and specialty pharmacy channels: These would be the practical buying and distribution environments for future commercial products.
• Payers: In oncology, reimbursement is a critical part of commercialization. Payers are not the end users, but they strongly influence access, step edits, and net pricing.
• Diagnostic ecosystem participants: For biomarker-driven use cases, laboratories and testing pathways matter because they affect how eligible patients are identified.
• Patients: Patients are the ultimate users, but economically Arvinas is more dependent on physicians, payers, and partners than on direct-to-consumer demand.

At this stage, Arvinas is economically concentrated: collaboration partners matter more than a broad set of end customers because the company is not yet commercial. Over time, that could shift if it launches products and broadens its oncology footprint.

8. What Is the Sales Model of Arvinas?

Arvinas’s sales model today is primarily a business-development and alliance-management model, not a traditional pharmaceutical field-sales model.

• Current model: The company “sells” access to its science through collaboration structures, shared-development arrangements, and licensing economics. This means commercial-style selling is concentrated in partnering, negotiation, and governance rather than physician promotion.
• Vepdegestrant path: Public disclosures indicate a shared-development structure with Pfizer for vepdegestrant. That matters because it gives Arvinas access to larger commercial capabilities than it could efficiently build alone.
• Future specialty sales possibility: For wholly owned assets, Arvinas could eventually build or buy a focused specialty oncology sales force, especially in the United States, if a program is sufficiently attractive.
• Channel implications: A partnered model improves reach and reduces infrastructure burden, but also reduces control and economic capture. A direct specialty-sales model would increase customer intimacy and strategic control, but would require higher fixed cost and operational complexity.

For consultants, this channel structure is important because it creates practical questions around launch design, territory strategy, alliance governance, and the make-versus-partner decision for future assets.

9. In What Geographies Does Arvinas Operate?

Arvinas is operationally concentrated in the United States but strategically global.

• Corporate and research base: Arvinas’s headquarters and core research operations are in New Haven, Connecticut.
• Clinical footprint: The company’s development activities extend across multiple countries through clinical trial sites, contract research organizations, and collaborators.
• Commercial reach through partners: Arvinas’s own commercial infrastructure is limited, but its larger partners provide a path to ex-U.S. development and commercialization.
• Manufacturing footprint: As is typical for a company at this stage, manufacturing appears to rely significantly on external partners rather than a large owned plant network.

That means Arvinas is not geographically diversified in the same way a large pharmaceutical company is. Its internal footprint is relatively focused, but the markets it is trying to reach are global oncology markets.

10. Who Are the Owners of Arvinas?

Arvinas is a publicly traded company and, based on recent proxy-season and beneficial ownership disclosures, it does not appear to have a controlling shareholder. Ownership is primarily institutional. Public filings have identified significant healthcare-focused and passive institutional investors, including Baker Bros. Advisors as a notable holder, while positions of other large asset managers can change over time. For investors or counterparties, the practical takeaway is that Arvinas is governed as a widely held biotech rather than a founder-controlled company.

11. How Is Arvinas Organized?

Arvinas reports one operating and reportable segment, which is typical for a clinical-stage biotechnology company. In practical terms, however, the business is organized around a few distinct operating lenses.

• Research and platform discovery: Teams focused on target selection, degrader design, medicinal chemistry, and preclinical biology.
• Development organization: Clinical development, translational medicine, biometrics, regulatory affairs, and medical functions that move candidates through human studies.
• Technical operations: Chemistry, manufacturing, and controls, supply planning, and oversight of external manufacturing partners.
• Alliance and business development: Management of relationships with partners such as Pfizer and any other active collaborators.
• Corporate functions: Finance, legal, intellectual property, human resources, and public-company infrastructure.

Another useful way to view Arvinas is by portfolio ownership structure: partnered programs, wholly owned clinical programs, and earlier-stage discovery assets. That internal distinction matters strategically even though it is not reported as separate accounting segments.

12. How Does Arvinas Operate?

Day to day, Arvinas operates like a science-driven drug developer with a substantial outsourced execution layer.

1. Target identification and degrader design: The company selects disease-relevant proteins and designs bifunctional molecules intended to recruit the cell’s degradation machinery.
2. Preclinical optimization: Compounds are screened for potency, selectivity, degradation efficiency, oral bioavailability, safety signals, and manufacturability.
3. Translational and biomarker work: Arvinas must connect target degradation to expected patient benefit and identify biomarkers that improve trial design and commercial positioning.
4. Clinical execution: The company runs or co-runs studies through investigators, hospitals, and contract research organizations, managing enrollment, data quality, and regulatory interactions.
5. External manufacturing oversight: Clinical supply and process development are managed through external manufacturing partners, which requires strong vendor governance and chemistry, manufacturing, and controls discipline.
6. Alliance management: For partnered assets, Arvinas must coordinate decision-making, development plans, budgets, and data sharing with larger pharmaceutical companies.

The main operating bottlenecks are typical biotech bottlenecks: turning elegant biology into robust human data, enrolling the right patients, scaling clinical manufacturing without setbacks, and deciding where to spend scarce capital across competing programs.

13. What Are the Growth Opportunities for Arvinas?

Arvinas’s most plausible growth opportunities are tied to clinical success, indication expansion, and platform monetization.

• Vepdegestrant commercialization: The largest opportunity is successful development and eventual launch of vepdegestrant in breast cancer. If the asset reaches the market with differentiated data, it could validate both the specific program and the broader degradation approach.
• Label expansion: Breast-cancer growth would not necessarily stop with one line of therapy. Combination regimens, earlier-line treatment settings, and biomarker-defined subgroups could materially expand the opportunity if supported by data.
• ARV-766 and prostate-cancer expansion: A successful wholly owned prostate-cancer program would give Arvinas higher retained economics and more strategic independence.
• Pipeline breadth: Additional successful degraders would make Arvinas less dependent on one asset and could support a multi-franchise oncology strategy over time.
• New collaborations: Partnerships remain a realistic growth vector, especially if Arvinas can keep showing that its platform is repeatable across targets.
• Geographic reach via partners: Because Arvinas is not building full global infrastructure alone, partner-led commercialization can extend market reach without equivalent fixed-cost expansion.

The main constraints are equally clear: clinical failure risk, competition from other endocrine and prostate-cancer therapies, regulatory uncertainty, dependence on partners in key programs, and the capital intensity of late-stage development.

14. What Is the History of Arvinas?

• 2013: Arvinas was founded to commercialize targeted protein degradation research associated with Yale scientist Craig Crews, one of the scientific pioneers behind the PROTAC concept.
• 2013-2018: The company built out its platform, assembled management and scientific teams, and advanced early discovery programs designed to show that targeted degradation could produce drug-like candidates.
• 2018: Arvinas completed its initial public offering on Nasdaq, giving it access to public-market capital to fund clinical development.
• 2020: The company announced a major collaboration with Genentech, validating broader external interest in its platform.
• 2021: Arvinas announced a major collaboration with Pfizer centered on vepdegestrant, significantly increasing the resources behind the breast-cancer program.
• 2022 onward: Arvinas increasingly shifted from a platform-validation story toward a late-stage execution story as lead assets moved deeper into the clinic.
• FY2024 and beyond: The company’s history became increasingly defined by whether it could turn scientific leadership in targeted protein degradation into registrational data, commercial preparation, and a broader pipeline.

15. What Is the Technology Strategy of Arvinas?

Technology is central to Arvinas’s identity. But in Arvinas’s case, “technology strategy” is not mainly about enterprise software or digital systems. It is about building a repeatable chemical-biology engine for targeted protein degradation.

The core strategy is to use degrader design capabilities, structural biology, linker chemistry, ligands for E3 ligases, proteomics, and translational assays to create oral medicines that induce the destruction of disease-relevant proteins. This matters because many proteins are difficult to drug well with classic inhibitor chemistry. If degradation works where inhibition has fallen short, Arvinas can create differentiated assets rather than marginal follow-ons.

There are two layers to the technology strategy. First, the platform is an internal engine for generating candidates. Second, it is part of the external value proposition to partners and investors. That means Arvinas must continually show that the platform is not a one-off invention tied to a single asset, but a scalable source of multiple drug candidates with credible intellectual-property protection.

16. What Is the R&D Strategy of Arvinas?

Arvinas’s research and development strategy is to concentrate spending on targets where degradation may offer a biologically meaningful advantage, while balancing near-term clinical value creation against longer-term platform breadth.

• Prioritize clinically translatable targets: The company has focused first on high-value oncology targets where the biology is well understood and where degradation may improve on inhibition or endocrine blockade.
• Use lead programs to validate the platform: Vepdegestrant and ARV-766 are not just assets; they are proof points for the modality.
• Invest in translational medicine: Biomarkers, resistance mechanisms, and patient-selection logic are especially important in competitive oncology indications.
• Maintain a pipeline beyond the lead assets: Earlier candidates are essential if Arvinas wants to remain a platform company rather than mature into a single-product biotech.
• Blend partnered and wholly owned R&D: Partnered programs reduce funding pressure; wholly owned programs preserve more upside if successful.

As with most development-stage biotechs, R&D is the largest strategic use of capital. The company’s challenge is not whether to invest in R&D, but how to sequence that investment so the platform keeps generating options without overwhelming the balance sheet.

17. What Is the Finance Strategy of Arvinas?

Arvinas’s finance strategy is fundamentally about funding innovation while preserving optionality. This is typical for a clinical-stage biotech, but Arvinas has some important specifics.

• Rely on collaboration economics and equity more than leverage: The company has historically funded itself through public-market capital and collaboration cash rather than through a highly levered balance sheet.
• Use partnerships to reduce burn on major programs: The Pfizer collaboration helps Arvinas participate in a large breast-cancer opportunity without having to self-fund the entire program globally.
• Prioritize cash runway over near-term earnings optics: Because the company is still development-stage, the key finance questions are liquidity, trial funding, and capital efficiency, not dividends or buybacks.
• Allocate capital selectively across the pipeline: Finance strategy and portfolio strategy are tightly linked. A late-stage partnered asset, a wholly owned clinical asset, and an early discovery asset have very different capital requirements and risk profiles.
• Maintain flexibility for commercialization: If a lead asset moves toward launch, Arvinas may need to fund medical affairs, market access, and selected commercial capabilities, so preserving financing flexibility matters.

For Arvinas, good finance strategy is not about maximizing short-term margins. It is about ensuring the company can reach the next major clinical and regulatory value inflection points without taking avoidable financing risk.

18. How Companies Like Arvinas Leverage Independent Consultants through Umbrex

For a company like Arvinas, the most useful outside consulting work is often highly specialized, time-bound, and tied to a major inflection point such as pivotal data, launch preparation, alliance decisions, or operating-model change. Umbrex has grown a global community of more than 8,000 independent management consultants based in more than 50 countries. These consultants are alumni of McKinsey, Bain, BCG, and other top firms. Companies like Arvinas use Umbrex when they need top-tier strategy, operations, organization, finance, technology, ERP, or AI talent without hiring a full consulting team with the overhead of a large firm.

• Develop a launch-readiness plan for vepdegestrant, including market sizing, account prioritization, diagnostic-pathway mapping, and field-force design scenarios.
• Build an alliance-governance playbook for partnered commercialization and development, especially where decision rights and profit-sharing structures create complexity.
• Create a portfolio-prioritization model across vepdegestrant, ARV-766, earlier pipeline assets, and discovery-stage programs.
• Assess indication-expansion strategy for breast-cancer combinations and sequencing opportunities based on competitive trial readouts and payer implications.
• Design a commercialization operating model for the transition from pure R&D biotech to hybrid development-and-commercial company.
• Improve clinical-operations performance through trial-site activation analytics, vendor-governance redesign, and enrollment acceleration initiatives.
• Support chemistry, manufacturing, and controls network strategy, including contract manufacturer selection, supply-risk mapping, and clinical-to-commercial scale-up planning.
• Develop global pricing and market-access scenarios for oncology launch planning, especially in settings where biomarker-defined positioning affects value demonstration.
• Conduct competitive intelligence and strategic war-gaming against other estrogen-receptor and androgen-receptor programs, including launch-timing implications.
• Evaluate business-development opportunities, such as new platform partnerships, regional licensing options, or make-versus-partner decisions for future wholly owned assets.